FDA advises on adaptive trials, simulations

The FDA describes concerns and considerations in the draft guidance on adaptive clinical trials released last week. The regulator says that trial simulations performed prior to a study can help evaluate the design options and the clinical scenarios that might take place when the study is actually conducted. It finds that simulations can be "an important planning tool in assessing the statistical properties of a trial design and the inferential statistics used in the data analysis." Content guidance is included for reporting trial simulations. Draft guidance

Suggested Articles

There's no evidence personal patient information leaked during the 11-week breach, but the same can't be said about Sangamo's own secrets.

Through a new online tracker, AllTrials names sponsors who fail to report clinical trial results on time per the FDAAA Final Rule.

The new solution aims to streamline the incorporation of human genomic data into clinical trial designs.